FMP
EURONEXT
TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET for osseointegration and bone remodelling; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid with anti-inflammatory properties that promotes the effect of active components, as well as acts as a cell colonization supporting tissue regeneration. The company was incorporated in 2017 and is headquartered in Jumet, Belgium.
0.71 EUR
-0.068 (-9.58%)
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)